iRhythm Technologies has collaborated with Alphabet’s health venture Verily to develop new technology for screening, diagnosing and managing atrial fibrillation (AFib) patients.
AFib is a common form of irregular heart rhythm that can multiply a person’s risk of severe or fatal stroke.
The partnership will leverage iRhythm’s AI-based diagnosis of arrhythmia, along with Verily’s analytics of health data to find a solution for AFib, which affects around 10 million Americans.
The main focus of the collaboration is to find a solution for asymptomatic AFib, in patients who are unaware they have the condition.
Under the terms of collaboration, both companies will work towards a solution that can provide early warnings, which can help to identify and manage the patient before the onset of a stroke.
Verily chief medical and scientific officer Dr Jessica Mega said: “With the high prevalence of cardiovascular-related health issues, we have an opportunity to not only improve how we diagnose, manage and monitor conditions like atrial fibrillation but also develop patient-centric solutions that could ultimately prevent serious cardiac events.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
iRhythm CEO and president Kevin King said: “Verily’s patient-centric approach to disease management and advanced hardware capabilities will prove critical in providing patients and providers with the tools needed to increase the efficiency of heart healthcare.”
According to the agreement, Verily will receive an upfront payment of $5m from iRhythm. The deal also involves potential milestone payments of up to $12.5m.
Last year, Janssen Pharmaceutical announced the encouraging one-year results from the mSToPS clinical trial that evaluated the wearable continuous electrocardiogram (ECG) monitoring iRhythm ZIO XT Patch to identify AFib.
The single-use, 14-day wearable sensor is designed to monitor and retain data from the continuous ECG of the user for up to two weeks.
Trial data revealed that the patch could identify those with AFib earlier and more efficiently than standard care. The home-based trial took place in alliance with Scripps Translational Science Institute (STSI), Aetna and iRhythm Technologies.